Amylou C. Dueck
A5090009905- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Cancer survivorship and care
- Health Systems, Economic Evaluations, Quality of Life
- HER2/EGFR in Cancer Research
- Acute Myeloid Leukemia Research
- Platelet Disorders and Treatments
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Eosinophilic Disorders and Syndromes
- Economic and Financial Impacts of Cancer
- Heterotopic Ossification and Related Conditions
- Statistical Methods in Clinical Trials
- Kruppel-like factors research
- Advanced Breast Cancer Therapies
- Childhood Cancer Survivors' Quality of Life
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Palliative Care and End-of-Life Issues
- Hemoglobinopathies and Related Disorders
- Lymphoma Diagnosis and Treatment
- Dementia and Cognitive Impairment Research
- Radiomics and Machine Learning in Medical Imaging
- Breast Lesions and Carcinomas
- Monoclonal and Polyclonal Antibodies Research
Mayo Clinic in Arizona
2016-2025
Mayo Clinic Hospital
2012-2024
Mayo Clinic
2007-2024
Mayo Clinic in Florida
2015-2024
Dana-Farber Cancer Institute
2007-2024
Alliance Foundation Trials
2022-2024
WinnMed
2013-2024
Boston Medical Center
2024
University of North Carolina at Chapel Hill
2014-2023
Memorial Sloan Kettering Cancer Center
2014-2023
Purpose There is growing interest to enhance symptom monitoring during routine cancer care using patient-reported outcomes, but evidence of impact on clinical outcomes limited. Methods We randomly assigned patients receiving outpatient chemotherapy for advanced solid tumors at Memorial Sloan Kettering Cancer Center report 12 common symptoms via tablet computers or receive usual consisting the discretion clinicians. Those with home received weekly e-mail prompts between visits. Treating...
The standard approach for documenting symptomatic adverse events (AEs) in cancer clinical trials involves investigator reporting using the National Cancer Institute's (NCI's) Common Terminology Criteria Adverse Events (CTCAE). Because this underdetects AEs, NCI issued two contracts to create a patient-reported outcome (PRO) measurement system as companion CTCAE, called PRO-CTCAE. This Commentary describes development of PRO-CTCAE by group multidisciplinary investigators and patient...
To integrate the patient perspective into adverse event reporting, National Cancer Institute developed a patient-reported outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE).
The APOE ε4 allele is associated with the risk of late-onset Alzheimer's disease. age at which memory decline diverges among persons who are homozygous for allele, those heterozygous and noncarriers unknown.
This study reports 2-year survival outcomes among patients with advanced nonprogressive stage IIA to IV lung cancer randomized symptom monitoring during chemotherapy via web-based patient-reported vs standard scheduled imaging after treatment detect symptomatic recurrence.
Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development MPN-directed therapies. We aimed assess utility an abbreviated symptom score for most pertinent representative MPN subsequent serial use assessing response therapy.The Neoplasm Symptom Assessment Form total (MPN-SAF TSS) was calculated as mean 10 items from two previously validated scoring systems. Questions focus on fatigue,...
Desmoid tumors (also referred to as aggressive fibromatosis) are connective tissue neoplasms that can arise in any anatomical location and infiltrate the mesentery, neurovascular structures, visceral organs. There is no standard of care.In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid receive either sorafenib (400-mg tablet once daily) matching placebo. Crossover group was permitted for placebo who had disease...
Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in neoadjuvant setting, but their role as adjuvant therapy remains uncertain. Methods In Adjuvant and/or Trastuzumab Treatment Optimization trial, patients with centrally confirmed early were randomly assigned to 1 year of T, L, sequence (T→L), or combination (L+T). The primary end point was disease-free survival...
Pelvic radiation plus sensitizing chemotherapy with a fluoropyrimidine (chemoradiotherapy) before surgery is standard care for locally advanced rectal cancer in North America. Whether neoadjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) can be used lieu of chemoradiotherapy uncertain. Download PDF the Research Summary. We conducted multicenter, unblinded, noninferiority, randomized trial FOLFOX (with given only if primary tumor decreased size by <20% or was discontinued because...
Electronic systems that facilitate patient-reported outcome (PRO) surveys for patients with cancer may detect symptoms early and prompt clinicians to intervene.To evaluate whether electronic symptom monitoring during treatment confers benefits on quality-of-life outcomes.Report of secondary outcomes from the PRO-TECT (Alliance AFT-39) cluster randomized trial in 52 US community oncology practices PRO or usual care. Between October 2017 March 2020, 1191 adults being treated metastatic were...
Abstract Background Glioblastoma (GBM) exhibits profound intratumoral genetic heterogeneity. Each tumor comprises multiple genetically distinct clonal populations with different therapeutic sensitivities. This has implications for targeted therapy and informed paradigms. Contrast-enhanced (CE)-MRI conventional sampling techniques have failed to resolve this heterogeneity, particularly nonenhancing populations. study explores the feasibility of using multiparametric MRI texture analysis...
Purpose To develop a genomic signature that predicts benefit from trastuzumab in human epidermal growth factor receptor 2–positive breast cancer. Patients and Methods DASL technology was used to quantify mRNA samples 1,282 patients enrolled onto the Combination Chemotherapy With or Without Trastuzumab Treating Women Breast Cancer (North Central Treatment Group N9831 [NCCTG-N9831]) adjuvant trial. Cox proportional hazard ratios (HRs), adjusted for significant clinicopathologic risk factors,...
<h3>Importance</h3> Programs that analyze and report rates of surgical complications are an increasing focus quality improvement efforts. The most comprehensive tool currently used for outcomes monitoring in the United States is American College Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP). <h3>Objective</h3> To compare experienced by patients treated at hospitals did vs not participate NSQIP. <h3>Design, Setting, Participants</h3> Data from University HealthSystem...
Background: The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events is an item library designed eliciting patient-reported adverse events in oncology. For each event, up to three individual items are scored frequency, severity, and interference with daily activities. To align other standardized tools event assessment including Events, algorithm mapping any given a single composite numerical grade was developed tested. Methods: A five-step process used: (1)...
Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, potential value of adding palbociclib to endocrine therapy hormone receptor-positive cancer has not been confirmed.
The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera (PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) interferon-α (IFN-α) are the most frequently used cytoreductive options ET PV at high risk vascular complications. Myeloproliferative Disorders Research Consortium 112 was an investigator-initiated, phase 3 trial comparing HU pegylated IFN-α (PEG) in treatment-naïve, high-risk ET/PV. primary endpoint complete response...
The standard of care for locally advanced rectal cancer in North America is neoadjuvant pelvic chemoradiation with fluorouracil (5FUCRT). Neoadjuvant chemotherapy and oxaliplatin (FOLFOX) an alternative that may spare patients the morbidity radiation. Understanding relative patient experiences these options necessary to inform treatment decisions.